Last updated: October 30, 2026
PROCRIT, the epoetin alfa biologic marketed by Janssen, is a mature erythropoiesis-stimulating agent with substantially eroded exclusivity. Its commercial decline reflects FDA safety restrictions, reduced oncology use, dialysis-provider purchasing pressure, competition from Epogen and Aranesp, and biosimilar entry through Retacrit. The core patent estate no longer creates a material U.S. barrier to competition. Current value depends on institutional contracts, reimbursement, supply reliability, and clinical positioning rather than exclusivity.
What is PROCRIT and how is it used?
PROCRIT is recombinant human erythropoietin, or epoetin alfa. It stimulates red-blood-cell production and is administered by subcutaneous or intravenous injection.
The FDA-approved uses include:
- Anemia caused by chronic kidney disease.
- Chemotherapy-induced anemia in selected patients with non-myeloid malignancies.
- Reduction of allogeneic red-blood-cell transfusions in selected elective, noncardiac and nonvascular surgery.
- Anemia associated with zidovudine treatment in patients with HIV infection.
The FDA label carries a boxed warning for increased risks of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence in certain cancer settings. The label requires use of the lowest dose needed to reduce transfusion exposure and does not recommend hemoglobin normalization in chronic kidney disease or cancer patients.[1]
PROCRIT is a biologic product rather than a conventional small-molecule drug. Its primary U.S. competitors are:
| Product |
Active ingredient |
Sponsor or manufacturer |
Competitive position |
| PROCRIT |
Epoetin alfa |
Janssen |
Legacy originator brand |
| Epogen |
Epoetin alfa |
Amgen |
Major dialysis and nephrology competitor |
| Aranesp |
Darbepoetin alfa |
Amgen |
Longer-acting ESA |
| Retacrit |
Epoetin alfa-epbx |
Pfizer/Hospira |
FDA-approved biosimilar to epoetin alfa |
| Mircera |
Methoxy polyethylene glycol-epoetin beta |
Vifor Pharma/Roche relationship |
Long-acting ESA, primarily relevant in kidney disease |
When did PROCRIT lose exclusivity?
PROCRIT lost effective U.S. exclusivity well before the launch of Retacrit. The principal recombinant erythropoietin composition and production patents expired during the 2000s and early 2010s, depending on the patent, jurisdiction, and applicable patent-term adjustments.
Historical patent timeline
| Patent or patent family |
Subject matter |
Status and commercial relevance |
| U.S. Patent No. 4,703,008 |
Recombinant production of human erythropoietin |
Expired; foundational technology |
| U.S. Patent No. 5,441,868 |
Recombinant erythropoietin production and related cell technology |
Expired; no current U.S. blocking effect |
| U.S. Patent No. 5,547,933 |
Erythropoietin production technology |
Expired; historically relevant to manufacturing disputes |
| Later formulation and process patents |
Stability, purification, dosing, and manufacturing controls |
Mostly expired, nonblocking, or limited to specific processes |
Amgen was the principal innovator associated with recombinant epoetin alfa. Johnson & Johnson commercialized epoetin alfa under the PROCRIT brand in the United States through its pharmaceutical organization, while Amgen marketed Epogen. The commercial arrangement created parallel branded epoetin franchises rather than a single originator product.[2]
The original patent estate protected recombinant erythropoietin production and related biological materials. It did not create a durable platform for controlling all later epoetin products. Current competitors can rely on the established biologic class, regulatory comparability, and independent manufacturing processes.
What is the FDA regulatory status of PROCRIT?
PROCRIT remains an FDA-approved epoetin alfa product under its biologics license and labeling. The commercial market is governed by the Biologics Price Competition and Innovation Act framework, not the traditional Hatch-Waxman framework used for most small molecules.
The FDA approved Retacrit, epoetin alfa-epbx, in 2018 as a biosimilar to Epogen and PROCRIT. Retacrit is not automatically interchangeable with PROCRIT solely because it is biosimilar. Interchangeability requires a separate FDA designation under the biosimilar pathway. Pharmacy substitution is therefore governed by state law and product-specific regulatory status.[3]
Does PROCRIT have Orange Book protection?
No. Biologic products are generally not listed in the FDA Orange Book in the same manner as conventional small-molecule drugs. The relevant FDA reference is the Purple Book, which identifies biological reference products and biosimilars.
Patent disputes involving biologics may proceed through the BPCIA patent-exchange process, federal litigation, or commercial settlement. Orange Book patent certification terms such as Paragraph IV apply primarily to abbreviated new drug applications, not to a biosimilar application for epoetin alfa.
How many patents currently protect PROCRIT?
No active U.S. composition-of-matter patent appears to provide a material commercial barrier to epoetin alfa competition. Historical patents covered recombinant DNA, host cells, expression systems, purification, and production methods. Any surviving rights would generally be narrower process or formulation claims rather than broad product exclusivity.
The practical patent strength of PROCRIT is therefore low:
| Patent category |
Current protection |
Business effect |
| Composition of matter |
Expired |
No broad product monopoly |
| Recombinant production |
Expired or commercially avoidable |
Limited manufacturing relevance |
| Formulation |
Narrow or expired |
Low barrier to biosimilar entry |
| Method of use |
Restricted by FDA label and safety rules |
Limited ability to block competing ESAs |
| Manufacturing know-how |
Potentially confidential |
Can affect cost and yield, but is not patent exclusivity |
| Trade secrets and quality systems |
Potentially important |
Operational barrier rather than legal exclusivity |
What formulation patents protect PROCRIT?
PROCRIT’s commercial protection has not depended on a durable formulation patent estate. Epoetin alfa products use established injectable formulations with excipients, protein-stability controls, and container-closure systems. These elements can be protected by narrow patents, manufacturing know-how, or regulatory controls, but they do not normally prevent biosimilar competition when the reference product’s patent barriers have expired.
The main formulation risks for competitors are protein aggregation, oxidation, adsorption to containers, particulate formation, and preservation of biological activity during storage. These are technical barriers that increase development and manufacturing costs. They do not restore originator exclusivity.
What method-of-use patents cover PROCRIT?
PROCRIT’s approved uses are broad therapeutic categories rather than a single proprietary indication. Method-of-use claims historically focused on treating anemia, reducing transfusions, and supporting patients receiving chemotherapy, dialysis, or surgery.
Method-of-use protection is weak in the current market for three reasons:
- Most foundational anemia-treatment claims are old.
- Biosimilar and generic-like competition can use indications that are not protected or can rely on labeling strategies that omit patented uses.
- ESA use is constrained by safety warnings, reimbursement rules, and treatment guidelines.
The greatest commercial restriction on oncology use is clinical and regulatory. ESA use declined after evidence linked higher hemoglobin targets and certain cancer settings with worse outcomes. The FDA revised labeling to narrow use and emphasize transfusion avoidance rather than normalization of hemoglobin.[1]
Which companies are challenging PROCRIT?
The leading competitive threats come from companies that already have approved ESA products rather than from pending Paragraph IV generic applicants.
| Company |
Product |
Threat to PROCRIT |
| Pfizer and Hospira |
Retacrit |
Direct biosimilar competition to epoetin alfa |
| Amgen |
Epogen |
Same-molecule branded competition |
| Amgen |
Aranesp |
Longer-acting substitution in chronic kidney disease and oncology |
| Vifor Pharma and commercial partners |
Mircera |
Long-acting alternative in kidney disease |
| Hospital and dialysis providers |
Contracted ESA sourcing |
Purchasing pressure and conversion risk |
Retacrit is the most direct post-exclusivity threat because it is a biosimilar epoetin alfa product. Epogen remains important because dialysis providers may use contracting, bundled reimbursement, and formulary decisions to shift volume between epoetin products.
What is the financial trajectory of PROCRIT?
PROCRIT’s financial trajectory is a long-term decline from a multibillion-dollar anemia franchise to a mature, price-sensitive biologic business. Public reporting has become less transparent because Johnson & Johnson has not consistently disclosed PROCRIT as a standalone current revenue line.
Main revenue phases
| Period |
Financial condition |
Primary drivers |
| Late 1990s to mid-2000s |
High-growth and peak-franchise period |
Broad anemia use, limited biosimilar competition, strong oncology demand |
| Late 2000s to early 2010s |
Declining but large revenue base |
Safety restrictions, patent expiry, reduced oncology use |
| Mid-2010s |
Accelerated erosion |
ESA utilization decline, payer pressure, competitor switching |
| 2018 onward |
Mature and increasingly commoditized |
Retacrit entry, contracting, lower net pricing, limited standalone disclosure |
Janssen’s historical reports showed a sustained fall in PROCRIT sales as treatment guidelines tightened and physicians reduced use in cancer patients. The decline was part of a broader contraction in the ESA market, not solely a patent event.[4]
The most important financial variables are:
- Net price after hospital, dialysis, and group-purchasing discounts.
- Volume retained in nephrology and dialysis.
- Conversion to Retacrit or Epogen.
- Reimbursement under Medicare dialysis and outpatient payment systems.
- Manufacturing cost per syringe or vial.
- Supply reliability and tender wins.
- Remaining brand preference among hospitals and specialists.
PROCRIT is more exposed to institutional procurement than to retail pharmacy demand. Dialysis organizations, hospitals, integrated delivery networks, and specialty distributors can negotiate materially lower prices than ordinary retail channels.
How does PROCRIT compare with Epogen, Aranesp, and Retacrit?
| Factor |
PROCRIT |
Epogen |
Aranesp |
Retacrit |
| Molecule |
Epoetin alfa |
Epoetin alfa |
Darbepoetin alfa |
Epoetin alfa-epbx |
| Regulatory status |
Originator biologic |
Originator biologic |
Originator biologic |
Biosimilar |
| Dosing profile |
Shorter-acting |
Shorter-acting |
Longer-acting |
Shorter-acting |
| Patent position |
Mature, expired core estate |
Mature, expired core estate |
Mature, reduced protection |
No originator patent barrier |
| Main channel |
Hospitals, oncology, kidney care |
Dialysis and kidney care |
Kidney care and oncology |
Institutional and payer-contracted use |
| Price pressure |
High |
High |
Moderate to high |
High |
| Differentiation |
Brand familiarity and supply |
Dialysis relationships |
Dosing convenience |
Lower-cost biologic alternative |
Aranesp can retain value where less frequent dosing offsets acquisition-price differences. Retacrit has the clearest substitution proposition because it directly targets epoetin alfa demand at a potentially lower net cost.
What patent litigation and settlements affect PROCRIT?
The major legal history centers on foundational recombinant erythropoietin patents and the division of commercial rights between Amgen and Johnson & Johnson. Those disputes shaped the branded market but do not create a current U.S. barrier equivalent to an active composition patent.
Current litigation risk is more likely to arise from:
- Biosimilar manufacturing patents.
- Cell-line and purification claims.
- Labeling and interchangeability disputes.
- Contracting and antitrust issues.
- Patent challenges involving later-generation ESAs.
- Product liability claims tied to ESA safety warnings.
There is no current, widely recognized PROCRIT settlement that restores meaningful U.S. market exclusivity against Retacrit or other established epoetin competition. Commercial agreements are more likely to govern supply, distribution, and institutional pricing than market-wide patent exclusion.
What generic launch scenarios exist for PROCRIT?
Because PROCRIT is a biologic, the relevant launch scenario is biosimilar entry rather than a conventional ANDA generic launch.
Scenario 1: Continued originator erosion
PROCRIT retains a smaller share of hospital and specialist accounts while competing through service, supply continuity, and existing contracts. Revenue falls gradually as price concessions increase.
Scenario 2: Accelerated biosimilar conversion
Health systems and dialysis providers shift volume to Retacrit or another lower-cost epoetin product. PROCRIT experiences both volume loss and net-price compression.
Scenario 3: Stable niche demand
Some providers retain PROCRIT because of established protocols, procurement arrangements, clinical familiarity, or supply concerns. This scenario limits the speed of decline but does not restore pricing power.
Scenario 4: ESA class contraction
Lower utilization in oncology and restrictive hemoglobin targets in chronic kidney disease reduce the total market. In this case, PROCRIT can lose revenue even if its share remains stable.
How strong is the PROCRIT patent estate?
The estate is weak as a current exclusivity asset and moderate as a historical technology estate.
Its strengths are:
- Long clinical and manufacturing history.
- Established regulatory record.
- Brand recognition among institutional buyers.
- Proven quality-control and supply infrastructure.
Its weaknesses are:
- Expired foundational patents.
- Direct biosimilar competition.
- Limited formulation differentiation.
- High payer and dialysis-provider bargaining power.
- Reduced clinical use in oncology.
- No durable Orange Book-style patent shield.
Geographic protection is also uneven. U.S. core patents have expired, while foreign markets may have had different patent terms, supplementary protection certificates, regulatory exclusivities, or local litigation outcomes. Those differences are unlikely to create a durable global moat because epoetin alfa is a mature biologic with multiple regional suppliers.
Key Takeaways
- PROCRIT is a mature epoetin alfa biologic with no meaningful remaining U.S. composition-patent exclusivity.
- Retacrit is the principal direct biosimilar competitor and was FDA-approved in 2018.
- Epogen remains a major same-molecule competitor, while Aranesp competes through longer-acting dosing.
- FDA safety restrictions sharply reduced oncology ESA use and limited hemoglobin targets in chronic kidney disease.
- Current commercial value is driven by institutional contracts, reimbursement, supply, and manufacturing economics.
- PROCRIT’s revenue trajectory is structurally negative, with standalone financial disclosure becoming less detailed over time.
- The patent estate is weak for blocking competition but the manufacturing and regulatory infrastructure remains commercially relevant.
- A conventional Paragraph IV generic launch is not the appropriate framework. Biosimilar competition under the BPCIA framework is the relevant risk.
FAQs
Is PROCRIT still available in the United States?
PROCRIT remains an FDA-approved epoetin alfa product. Its commercial position is narrower than during its peak period because of biosimilar competition and lower ESA utilization.
Is Retacrit interchangeable with PROCRIT?
Retacrit is FDA-approved as a biosimilar to epoetin alfa products. Biosimilarity does not by itself establish interchangeability. Substitution depends on FDA interchangeability status and applicable state law.
Does PROCRIT have an Orange Book patent listing?
Biologic products such as PROCRIT are generally not handled through Orange Book patent listings. The Purple Book and BPCIA framework are more relevant.
Can a generic company launch epoetin alfa without challenging a PROCRIT patent?
A conventional generic cannot rely on an ANDA pathway for a biologic reference product. A competitor generally uses the biosimilar pathway or another applicable biologics approval route.
What is the largest remaining commercial risk to PROCRIT?
The largest risk is cumulative price and volume erosion from Retacrit, Epogen, and institutional contracting, combined with declining ESA use in oncology and stricter safety-driven treatment practices.
References
- U.S. Food and Drug Administration. (2023). PROCRIT (epoetin alfa) prescribing information.
- Johnson & Johnson. (Various years). Annual reports and Form 10-K filings.
- U.S. Food and Drug Administration. (2018). Retacrit (epoetin alfa-epbx) prescribing information and biosimilar approval materials.
- U.S. Food and Drug Administration. (2011). Erythropoiesis-stimulating agents: revised labeling and safety communications.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
